GlassScriptPhysician profile
Alan S Brau
NPI 1134156938
$14,307.22
in general payments reported to CMS, 2019-2025
41 companies · $3,413 in 2025
The $3,413 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,528 · 2020: $472 · 2021: $959 · 2022: $1,357 · 2023: $3,390 · 2024: $3,188 · 2025: $3,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,687 · Travel and Lodging: $788 · Education: $516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,686.76 |
| Travel and Lodging | $787.96 |
| Education | $516.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,289.59 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Harmony Biosciences LLC | $1,741.52 | 2020-2025 | Wakix |
| Glaxosmithkline, LLC. | $1,635.08 | 2019-2025 | Nucala |
| Inspire Medical Systems, INC. | $1,583.63 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $1,092.25 | 2019-2025 | |
| Genzyme Corporation | $686.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $622.22 | 2019-2024 | Stiolto Respimat, Spiriva Respimat, Combivent Respimat |
| Mallinckrodt Hospital Products INC. | $570.35 | 2022-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $473.79 | 2019-2025 | Opsumit, Uptravi |
| Philips North America LLC | $459.28 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy, Reusable Vest |
| Regeneron Healthcare Solutions, INC. | $435.75 | 2021-2025 | Dupixent |
| Axsome Therapeutics, INC. | $421.30 | 2023-2025 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $311.67 | 2023-2025 | Lumryz |
| Amgen INC. | $231.14 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $206.07 | 2019-2023 | Xolair |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $204.20 | 2019-2024 | Yupelri |
| Optinose US, INC. | $190.11 | 2023-2024 | |
| Viatris Specialty LLC | $146.25 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $103.35 | 2023-2025 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Merck Sharp & Dohme LLC | $89.87 | 2021-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $81.86 | 2020-2023 | Aralast |
| Sunovion Pharmaceuticals INC. | $63.51 | 2019 | |
| Verona Pharma, INC. | $63.39 | 2025 | Ohtuvayre |
| Idorsia Pharmaceuticals US INC | $61.90 | 2022-2025 | Quviviq, Quviviq |
| Insmed, INC. | $54.06 | 2025 | Brinsupri, Arikayce |
| United Therapeutics Corporation | $53.27 | 2019-2024 | Tyvaso |
| Grifols USA, LLC | $45.70 | 2020-2023 | Prolastin-C Liquid |
| Electromed, INC. | $45.34 | 2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $32.62 | 2019 | |
| Eisai INC. | $30.83 | 2020-2021 | |
| Csl Behring | $27.30 | 2020 | |
| Polynovo North America LLC | $21.80 | 2023 | |
| Ucb, INC. | $20.79 | 2019 | |
| Phadia US INC. | $19.54 | 2025 | Immunocap |
| Inogen, INC. | $18.81 | 2023 | Inogen One G3 Oxygen Concentrator |
| Lilly USA, LLC | $18.79 | 2025 | Zepbound |
| Advanced Respiratory, INC | $16.81 | 2021 | |
| Aytu Biopharma, INC. | $13.83 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.94 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Brau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.